Contact this trialFirst, we need to learn more about you.
Anti-inflammatory Agent
DFV890 +1 More for Coronary Heart Disease
Recruiting0 awardsPhase 2
Montreal, Quebec
This trial will test the safety and effectiveness of increasing doses of a daily oral medication called DFV890 for 12 weeks in 28 people with coronary heart disease and specific genetic mutations. The goal is
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.